RNAC Reports $120.4M Cash, $19.5M R&D, Initiates Phase 2 TRITON Myositis Trial, Enrolls Pediatric JDM in HELIOS, Supports Ops to Mid‑2027
Cartesian Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $6.92
+37% in 7d after detection
Post-detection moves
1h
—
1d
0.0%
3d
+19%
7d
+37%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS